Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase 1 Study of KZR-261, a Small Molecule Sec61 Inhibitor, in Subjects With Advanced Solid Malignancies

Next Previous
X
Search
Trial Profile

A Phase 1 Study of KZR-261, a Small Molecule Sec61 Inhibitor, in Subjects With Advanced Solid Malignancies

Status: Active, no longer recruiting
Phase of Trial: Phase I

Latest Information Update: 21 Aug 2024

Price :

$35 *

Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs KZR 261 (Primary)
  • Indications Colorectal cancer; Malignant melanoma; Mesothelioma; Prostate cancer; Solid tumours; Uveal melanoma
  • Focus Adverse reactions; First in man; Pharmacokinetics
  • Sponsors Kezar Life Sciences

    • Most Recent Events

    • 13 Aug 2024 Status changed from recruiting to active, no longer recruiting, according to a Kezar Life Sciences media release.
    • 13 Aug 2024 According to a Kezar Life Sciences media release, full data will be presented at a medical conference following completion of the study. A total of 61 patients enrolled across the dose-escalation and dose expansion portions of the study, which included seven patients enrolled in the melanoma cohort of the dose-expansion portion at a dose level of 60 mg/m2. Enrollment has been stopped in the KZR-261 Phase 1 study, and clinical resources are being reallocated toward development of zetomipzomib.
    • 09 May 2024 According to a Kezar Life Sciences media release, a total of 43 patients have been enrolled in the dose escalation part of the trial to date and additional backfill patients may be added to better understand the safety, pharmacokinetics, and pharmacodynamics of KZR-261 at specific dose levels. The study is currently enrolling the dose expansion part of the study with a cohort of melanoma patients at a dose level of 60 mg/m2.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top